Important research recently published in the American Heart Association’s journals illustrates that the cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the US remain poorly described. The study consisted of a cross-sectional analysis of 1295 adults with heterozygous FH enrolled in the FH Foundation’s CASCADE-FH Registry from 11 US lipid…

Read More

by Seth J. Baum, MD A recent article by Caroline Humer and Ransdell Pierson for Reuters reported on the unexpectedly paltry number of prescriptions for PCSK9 inhibitors, the revolutionary cholesterol lowering drugs that were FDA approved in the summer of 2015. Insurance providers had viewed these costly medications as a potentially grave threat to their…

Read More

by Seth J. Baum, MD Flying back from the FH Foundation’s third annual FH Summit I was suffused by assorted feelings and thoughts. I attend many meetings; yet, this one is unique. A conglomerate of stakeholders congregate to discuss past, present, and future issues about a disease that has only recently captured the hearts, minds,…

Read More

by Seth J. Baum, MD It’s National Cholesterol Education Month and we have fittingly entered a new era in lipid management. We now know that elevated LDL cholesterol causes heart attacks and strokes. Studies of all types have proved this. The most persuasive proof comes from genetics, specifically Mendelian Randomization studies. Recently our increased genetic…

Read More

by Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA Every generation or so, each medical discipline hopes to experience a revolution of monumental proportions. Statins, released in the 1980s, were the last cholesterol modifying medications that dramatically altered our ability to decrease heart attacks and strokes. Now we have the PCSK9 inhibitors. With them we…

Read More